Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: " One time lump sums are too expensive for some companies"

"These are 1-time license payments spread out in a "payment plan" type arrangement, not recurring royalties."

Maybe, maybe not; it is not clear from pr.

Note also: ".....companies have been awaiting the outcome of US'336 and are now reengaging in licensing discussions in light of the escalating royalty rate structure of the MMP Portfolio(TM) Licensing Program."

There have always been two routes offered: lump sums, and ongoing royalties. I like lump sums for various reasons, but it is not to say that a hybrid of these could not be negotiated. Time will tell.

Share
New Message
Please login to post a reply